01 January 2002
A radical approach to cancer.
Undurti DasMed Sci Monit 2002; 8(4): RA79-92 :: ID: 420857
Abstract
Reactive oxygen species are known to be potentially dangerous, but arealso needed for signal-transduction pathways. Tumor cells have relatively low amounts of superoxide dismutase(SOD), which quenches superoxide anion (O2(-*)), and as a result of a higher level of aerobic metabolism,higher concentrations of O2(-*) , compared to normal cells. But this may not be true of all tumor cells.Some tumor cells have relatively higher amounts of vitamin E, a potent anti-oxidant, and a higher levelof anaerobic metabolism, resulting in a balance that is tilted more towards higher anti-oxidant capacity.In both instances of higher aerobic and anaerobic metabolism methods designed to augment free radicalgeneration in tumor cells can cause their death. It is suggested that free radicals and lipid peroxidessuppress the expression of Bcl-2, activate caspases and shorten telomere, and thus inducing apoptosisof tumor cells. Ionizing radiation, anthracyclines, bleomycin and cytokines produce free radicals andthus are useful as anti-cancer agents. But they also produce many side-effects. 2-methoxyoestradiol andpolyunsaturated fatty acids (PUFAs) inhibit SODs and cause an increase of O2(-*) in tumor cells leadingto their death. In addition, PUFAs (especially gamma-linolenic acid), 2-methoxyoestradiol and thalidomidemay possess anti-angiogenic activity. This suggests that free radicals can suppress angiogenesis. Limitedclinical studies done with gamma-linolenic acid showed that it can regress human brain gliomas withoutany significant side-effects. Thus, PUFAs, thalidomide and 2-methoxyoestradiol or their derivatives mayoffer a new radical approach to the treatment of cancer.
Keywords: Anaerobiosis, Angiogenesis Inhibitors, Cell Division, Fatty Acids, Unsaturated, Free Radicals, Lipid Peroxidation, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Superoxides, Telomere, thalidomide, Vitamin E
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952